885270-77-9

Basic information

• Product Name: (2-AMINO-5-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: (2-AMINO-5-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER
• CAS NO: 885270-77-9
• Molecular Formula: C₁₂H₁₈N₂O₂
• Molecular Weight: 222.28
• Mol File: 885270-77-9.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2-AMINO-5-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (2-AMINO-5-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER(885270-77-9)
• EPA Substance Registry System: (2-AMINO-5-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER(885270-77-9)

Safety Data

• Hazardous Substances Data: 885270-77-9(Hazardous Substances Data)

Usage

General Description

"(2-Amino-5-methyl-phenyl)-carbamic acid tert-butyl ester" is a chemical compound with the molecular formula C12H17N3O2. It is an ester derivative of carbamic acid and has a molecular weight of 231.28 g/mol. This chemical is commonly used in the pharmaceutical industry as a building block for the synthesis of various biologically active compounds. It is also utilized in research and development for the production of new drugs. Additionally, (2-Amino-5-methyl-phenyl)-carbamic acid tert-butyl ester may have potential applications in the field of agriculture and as an intermediate for the production of other chemicals.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 496-72-0 4-methyl-1,2-diaminobenzene 
• 578-46-1 5-methyl-2-nitroaniline 
• 827-32-7 4-bromo-5-methyl-2-nitrophenylamine 

Downstream Products

• 1609929-53-4 1-acetyl-N-cyclohexyl-7-methyl-3-phenyl-1,4-dihydroquinoxaline-2-carboxamide 

Relevant articles and documents

2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors

A series of 2-aminopyrimidine derivatives were designed and synthesized as highly selective FGFR4 inhibitors. One of the most promising compounds 2n tightly bound FGFR4 with a Kd value of 3.3 nM and potently inhibited its enzymatic activity with an IC50 value of 2.6 nM, but completely spared FGFR1/2/3. The compound selectively suppressed proliferation of breast cancer cells harboring dysregulated FGFR4 signaling with an IC50 value of 0.38 μM. Furthermore, 2n exhibited extraordinary target specificity in a Kinome-wide screen against 468 kinases, with S(35) and S(10) selectivity scores of 0.01 and 0.007 at 1.0 μM, respectively.

Histone deacetylase inhibitors based on derivatives of tricyclic polyhydroacridine and analogs possessing fused saturated five- and seven-membered rings

The present invention refers to compounds of formula (I): as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or chemoprevention of cancer hematological malignancy, prolifera

MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF-176

Compounds of Formula 1, or pharmaceutically acceptable salts thereof: wherein X, R1, R2, R3, R4, R5, n, m, and p are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.